Breast Cancer Metastatic Clinical Trials
2 recruiting trials for Breast Cancer Metastatic. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Breast Cancer Metastatic clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 1 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by European Institute of Oncology (1), Solve Therapeutics (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is SLV-154 (drug, 1 trial).
Track Breast Cancer Metastatic trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
PIK3CA Mutational Status Assessment
Evaluation of PIK3CA mutational status: a route towards a tailored diagnostic approach.
SLV-154 Treatment of Metastatic Solid Tumors
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Breast Cancer Metastatic, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Breast Cancer Metastatic, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Breast Cancer Metastatic, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.